Quench Bio, a Cambridge, Mass.-based company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, completed a $50m Series A financing.
The round was led by RA Capital Management, with participation from new Investor Abbvie Ventures, with participation from Atlas Venture and Arix Bioscience plc (LSE: ARIX). In conjunction with the funding, Josh Resnick, M.D., Managing Director and co-head of Ventures at RA Capital, will join the Quench Bio board as a new director alongside Adam Houghton, Head of AbbVie Ventures. Other board members include Samantha Truex as CEO, Bruce Booth of Atlas Venture, Jonathan Tobin of Arix Bioscience, Herbert Waldmann, Director at the Max Planck Institute and Jo Viney, President, CSO and Co-Founder of Pandion Therapeutics.
Founded in 2018 by Atlas, Arix, Mark Tebbe, Ph.D., Chief Technology Officer, and Mike Nolan, Ph.D., Head of Biology, together with Arturo Zychlinsky and Herbert Waldmann, both Directors at The Max Planck Institute who collaborated with the Lead Discovery Center on inhibitors of NETosis and gasdermin, and led by Samantha Truex, CEO, Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases. Its lead compounds target and inhibit the pore-forming protein Gasdermin D, a central player in both pyroptosis and NETosis pathways that mediates the release of inflammatory cytokines, alarmins, DNA and NETs.